Across TCGA pan-cancer cohorts, HLA-G Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HLA-G data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher HLA-G Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HLA-G expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
SCLC, LIHC, and PRAD are the cancer types where HLA-G Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.